Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Lina Titievsky"'
Autor:
Lina Titievsky, Tilman Schuster, Ronnie Wang, Muhammad Younus, Andrew Palladino, Kabir Quazi, Michael P. Wajnrajch, Betina Hernandez, Pamela S. Becker, Neal J. Weinreb, Christina Chambers, Roy Mansfield, Louise Taylor, Li-Jung Tseng, Paige Kaplan
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 17, Iss 1, Pp 1-11 (2022)
Abstract Background Limited real-world data from routine clinical care are available on the safety and effectiveness of treatment with taliglucerase alfa in patients with Gaucher disease (GD). Methods Taliglucerase Alfa Surveillance (TALIAS), a multi
Externí odkaz:
https://doaj.org/article/a2312ba99d1246d0b5b5524f11be215f
Autor:
Rajeev Masson, Lina Titievsky, Douglas A. Corley, Wei Zhao, Alfredo R. Lopez, Jennifer Schneider, Jonathan G. Zaroff
Publikováno v:
Cancer Medicine, Vol 8, Iss 18, Pp 7913-7923 (2019)
Abstract Background There are limited data on the incidence of cardiovascular disease among cancer patients in the pre‐tyrosine kinase inhibitor (TKI) era. Such data are important in order to contextualize the incidence of various cardiovascular ou
Externí odkaz:
https://doaj.org/article/3c8b1b32690e4b2599b998750166874d
Autor:
Madlen Gazarian, Daniel B. Horton, Bruce Carleton, Alan C. Kinlaw, Greta Bushnell A, Angela S. Czaja, Geneviève Durrieu, Emily F. Gorman, Lina Titievsky, Julie Zito, Jonathan L. Slaughter, Susan dos Reis
Publikováno v:
Pharmacoepidemiology and Drug Safety.
Autor:
Lina Titievsky, Nataliya Volkova
Publikováno v:
Drug Development for Rare Diseases ISBN: 9781003080954
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8bbc789d7fcf35f54f623fc7a8020090
https://doi.org/10.1201/9781003080954-5
https://doi.org/10.1201/9781003080954-5
Autor:
LORI M. LAFFEL, JINGWEN LIU, LINA TITIEVSKY, KAITLIN HAGAN, TINA LIU, KEVAL CHANDARANA, JASON L. GAGLIA, WENDY WOLF, JEOFFREY BISPHAM, KATHERINE S.M. CHAPMAN, DANIEL FINAN, RICHARD M. BERGENSTAL
Publikováno v:
Diabetes. 71
Continuous glucose monitoring (CGM) metrics and self-reported disease characteristics (severe hypoglycemic events [SHEs], HbA1c) warrant further description in people with T1D using CGM and pumps, including hybrid closed-loop systems (HCLS) . We cond
Autor:
JEREMY PETTUS, JINGWEN LIU, LINA TITIEVSKY, KAITLIN HAGAN, TINA LIU, KEVAL CHANDARANA, JASON L. GAGLIA, WENDY WOLF, JEOFFREY BISPHAM, KATHERINE S.M. CHAPMAN, DANIEL FINAN, JENNIFER SHERR
Publikováno v:
Diabetes. 71
Trials of continuous glucose monitors (CGMs) and hybrid closed-loop systems (HCLS) demonstrate improvements in glycemia with reductions in hypoglycemia in T1D, but there is limited real-world data on how these technologies impact the prevalence of im
Autor:
Rosa Gini, Miriam C. J. M. Sturkenboom, Caitlin Dodd, Lieke van der Aa, Simon de Lusignan, Johnny Kahlert, Consuelo Huerta, Gino Picelli, Hanne-Dorthe Emborg, Chris McGee, C Willame, Lina Titievsky, Elisa Martín-Merino, Daniel Weibel, Giuseppe Roberto, Marco Villa
Publikováno v:
Willame, C, Dodd, C, van der Aa, L, Picelli, G, Emborg, H D, Kahlert, J, Gini, R, Huerta, C, Martín-Merino, E, McGee, C, de Lusignan, S, Roberto, G, Villa, M, Weibel, D, Titievsky, L & Sturkenboom, M C J M 2021, ' Incidence Rates of Autoimmune Diseases in European Healthcare Databases : A Contribution of the ADVANCE Project ', Drug Safety, vol. 44, no. 3, pp. 383-395 . https://doi.org/10.1007/s40264-020-01031-1
Drug Safety, 44(3), 383-395. Adis
Drug Safety
Drug Safety, 44(3), 383-395. Adis
Drug Safety
Introduction The public–private ADVANCE collaboration developed and tested a system to generate evidence on vaccine benefits and risks using European electronic healthcare databases. In the safety of vaccines, background incidence rates are key to
Autor:
Maarit H Kokki, Lina Titievsky, Miriam C. J. M. Sturkenboom, Simon de Lusignan, Patrick Mahy, Susan Hahné, Vincent Bauchau, Heidi J. Larson, Alena Khromava, Laurence Torcel-Pagnon, Tyra Grove Krause, Antonella Chiucchiuini, Piotr Kramarz, Xavier Kurz, Priya Bahri
Publikováno v:
Vaccine. 38:B1-B7
The influenza A/H1N1 pandemic in 2009 taught us that the monitoring of vaccine benefits and risks in Europe had potential for improvement if different public and private stakeholders would collaborate better (public health institutes (PHIs), regulato
Autor:
Giorgia Danieli, Caitlin Dodd, Consuelo Huerta-Alvarez, Vincent Bauchau, Klara Berencsi, Chris McGee, Tom De Smedt, Talita Duarte-Salles, Lara Tramontan, Ana Correa, Daniel Weibel, Hanne-Dorthe Emborg, François Haguinet, Gino Picelli, Kaatje Bollaerts, Olivia Mahaux, Lina Titievsky, Elisa Martín-Merino, Miriam C. J. M. Sturkenboom
Publikováno v:
Vaccine, 38, B38-B46. Elsevier
Weibel, D, Dodd, C, Mahaux, O, Haguinet, F, De Smedt, T, Duarte-Salles, T, Picelli, G, Tramontan, L, Danieli, G, Correa, A, McGee, C, Martín-Merino, E, Huerta-Alvarez, C, Berencsi, K, Emborg, H D, Bollaerts, K, Bauchau, V, Titievsky, L & Sturkenboom, M 2020, ' ADVANCE system testing : Can safety studies be conducted using electronic healthcare data? An example using pertussis vaccination ', Vaccine, vol. 38, pp. B38-B46 . https://doi.org/10.1016/j.vaccine.2019.06.040
Weibel, D, Dodd, C, Mahaux, O, Haguinet, F, De Smedt, T, Duarte-Salles, T, Picelli, G, Tramontan, L, Danieli, G, Correa, A, McGee, C, Martín-Merino, E, Huerta-Alvarez, C, Berencsi, K, Emborg, H D, Bollaerts, K, Bauchau, V, Titievsky, L & Sturkenboom, M 2020, ' ADVANCE system testing : Can safety studies be conducted using electronic healthcare data? An example using pertussis vaccination ', Vaccine, vol. 38, pp. B38-B46 . https://doi.org/10.1016/j.vaccine.2019.06.040
Introduction: The Accelerated Development of Vaccine benefit-risk Collaboration in Europe (ADVANCE) public-private collaboration, aimed to develop and test a system for rapid benefit-risk monitoring of vaccines using healthcare databases in Europe. T
Autor:
Vincent Bauchau, Talita Duarte-Salles, Rosa Gini, Claudia Bartolini, Lina Titievsky, Myint Tin Tin Htar, Marco Villa, Miriam C. J. M. Sturkenboom, Maria Alexandridou, Kaatje Bollaerts, Tom De Smedt, Hanne-Dorthe Emborg, Simon de Lusignan, Chris McGee
Publikováno v:
Vaccine. 38:B76-B83
Background The Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) is a public-private partnership aiming to develop and test a system for rapid benefit-risk (B/R) monitoring of vaccines using European electronic health